Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.

Trump told CNBC he will initially impose a “small tariff” on pharmas in the next week or so, but will raise it to 150% in a ...

Investors braced for the Federal Reserve's next interest rate decision and earnings from tech giants Microsoft and Meta.

Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne ...

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...

"This was primarily driven by 18% growth seen from the oncology portfolio, which has done well as a result of key drugs such ...

Shares of life sciences company Revvity (NYSE:RVTY) fell 7.6% in the afternoon session after the company lowered its ...

Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) fell 3.7% in the morning session after the company ...

The Food & Drug Administration is investigating the death of an 8‑year‑old following Elevidys gene therapy for Duchenne muscular dystrophy. U.S. distribution has been paused amid safety concerns.

Kraft's stock looks cheap, trading at 13 times its trailing earnings. But with many question marks around its business, the safest option is to take a wait-and-see approach.

NEW YORK, July 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and ...